{"id":1036517,"date":"2012-10-01T15:20:33","date_gmt":"2012-10-01T15:20:33","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/uncategorized\/sdix-sells-food-safety-and-gmo-businesses-to-romer-labs-for-13-5-million.php"},"modified":"2024-08-17T15:57:03","modified_gmt":"2024-08-17T19:57:03","slug":"sdix-sells-food-safety-and-gmo-businesses-to-romer-labs-for-13-5-million","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/sdix-sells-food-safety-and-gmo-businesses-to-romer-labs-for-13-5-million.php","title":{"rendered":"SDIX Sells Food Safety and GMO Businesses to Romer Labs for $13.5 Million"},"content":{"rendered":"<p><p>    NEWARK, Del.--(BUSINESS WIRE)--  <\/p>\n<p>        SDIX (SDIX),    a leading provider of biotechnology-based products and    services, today announced it has entered into an agreement to    sell the assets of its Food Safety and GMO businesses to Romer    Labs for $13.5 million. Following this transaction, the Company    will concentrate on its Life Science business. Romer Labs is    acquiring the intellectual property, current inventory and    commercial contracts, as well as the equipment for the two    businesses and will employ the current staff.  <\/p>\n<p>    Francis DiNuzzo, SDIXs President and CEO, commented, The sale    of our Food Safety and GMO businesses to Romer Labs, represents    a continued commitment to focus on our core Life Science    business, and our Advanced GAT technologies. We continue to    make important progress as we work to develop our Advanced GAT    technology which is targeted at the discovery of monoclonal    antibodies to be used in high value applications such as    biotherapeutics and biomarker discovery. The net cash from this    sale will strengthen our balance sheet and provide additional    investment flexibility for our Life Science businesses.  <\/p>\n<p>    The acquisition is expected to be completed during the fourth    quarter of 2012.  <\/p>\n<p>    Mr. DiNuzzo went on to say We are pleased to not only achieve    great value for SDIX shareholders, but also to place our Food    Safety and GMO assets in good hands with Romer Labs. I would    like to thank all our employees and customers as we wish Romer    Labs continued success with the RapidChek product line and GMO    business.  <\/p>\n<p>    About SDIX (www.sdix.com)  <\/p>\n<p>    SDIX is a biotechnology company with a core expertise in    creating better antigens, better antibodies and better assays    for the pharmaceutical and biotechnology markets. For over 20    years, SDIX has been a leading immuno-solutions company,    developing results-oriented and innovative antibody-based    solutions that enable customers to meet high performance    research, diagnostic and commercialization objectives. In the    life science market, SDIXs technology and capabilities are    being used to help discover disease mechanisms, facilitate    development of new drugs and provide antibodies and assays for    the diagnosis of disease.  <\/p>\n<p>    About Romer Labs  <\/p>\n<p>    Romer Labs, founded in Washington, MO, in 1982, is a leader in    diagnostic solutions for food and feed safety. It develops,    manufactures and markets test kits for food allergens,    mycotoxins, veterinary drug residues and other food    contaminants. The company also operates four accredited    full-service laboratories on three continents. Romer Labs has    facilities in Austria, Brazil, China, Malaysia, Singapore, UK    and the USA. For more than 30 years, Romer Labs has been a    trusted partner for the food and feed industry worldwide.  <\/p>\n<p>    This news release may contain forward-looking statements    reflecting SDIX's current expectations. When used in this press    release, words like anticipate, could, enable,    estimate, intend, expect, believe, can, potential,    will, should, project, plan and similar expressions as    they relate to SDIX are intended to identify said    forward-looking statements. Investors are cautioned that all    forward-looking statements involve risks and uncertainties,    which may cause actual results to differ from those anticipated    by SDIX at this time. Such risks and uncertainties include,    without limitation, changes in demand for products, the    application of our technologies to various uses, delays in    product development, delays in market acceptance of new    products, retention of customers and employees, adequate supply    of raw materials, inability to obtain or delays in obtaining    fourth party, or required government approvals, the ability to    meet increased market demand, competition, protection of    intellectual property, non-infringement of intellectual    property, seasonality, and other factors more fully described    in SDIX's public filings with the U.S. Securities and Exchange    Commission.  <\/p>\n<\/p>\n<p>Original post:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/sdix-sells-food-safety-gmo-130000016.html;_ylt=A2KJ3CaotGlQKz0A4jf_wgt.\" title=\"SDIX Sells Food Safety and GMO Businesses to Romer Labs for $13.5 Million\" rel=\"noopener\">SDIX Sells Food Safety and GMO Businesses to Romer Labs for $13.5 Million<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> NEWARK, Del.--(BUSINESS WIRE)-- SDIX (SDIX), a leading provider of biotechnology-based products and services, today announced it has entered into an agreement to sell the assets of its Food Safety and GMO businesses to Romer Labs for $13.5 million. Following this transaction, the Company will concentrate on its Life Science business.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/sdix-sells-food-safety-and-gmo-businesses-to-romer-labs-for-13-5-million.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246860],"tags":[],"class_list":["post-1036517","post","type-post","status-publish","format-standard","hentry","category-biotechnology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1036517"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1036517"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1036517\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1036517"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1036517"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1036517"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}